Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients

HTML  XML Download Download as PDF (Size: 2676KB)  PP. 1320-1327  
DOI: 10.4236/ijcm.2014.520169    3,460 Downloads   4,240 Views  Citations

ABSTRACT

Back ground: There are no published clinical data in hemodialysis (HD) patients with mineral bone disorder (CKD-MBD) regarding the effect of sevelamer hydrochloride on the absorption of the oral calcitriol. Objectives: The aim of the present study was to determine the association of the sevelamer hydrochloride and serum 1-25(OH)2D concentration during oral calcitriol therapy. Methods: This was a before-and-after study in HD patients. Forty-six patients co-administered with phosphate-binder and calcitriol for CKD-MBD therapy took lanthanum carbonate (LC) and sevelamer hydrochloride (SH) for 4 weeks, respectively with calcitriol. The serum 1-25(OH)2D concentration was assessed after each period. Results: Serum 1-25(OH)2D concentration was significantly reduced with co-administration of SH compared to LH (mean, calcitriol with LC→SH: 19.9 pg/ml → 14.2 pg/ml, p < 0.001). The mean dosage of calcitriol, LH and SH was 0.32 mcg/day, 1443 mg/day and 3897 mg/day, respectively. Conclusion: SH significantly reduced serum 1-25(OH)2D concentrations after oral calcitriol administration compared to LH in HD patients. When we use SH as a phosphate binder with calcitriol for HD patients with CKD-MBD, we should consider the inhibitory effect of SH on oral calcitriol absorption.

Share and Cite:

Matsushita, K. , Sato, K. , Unagami, K. , Nitta, K. and Tago, K. (2014) Effect of Sevelamer Hydrochloride on the Serum Calcitriol Concentration in Hemodialysis Patients. International Journal of Clinical Medicine, 5, 1320-1327. doi: 10.4236/ijcm.2014.520169.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.